OA10579A - Flavin derivatives as anti-viral agents - Google Patents

Flavin derivatives as anti-viral agents Download PDF

Info

Publication number
OA10579A
OA10579A OA60815A OA60815A OA10579A OA 10579 A OA10579 A OA 10579A OA 60815 A OA60815 A OA 60815A OA 60815 A OA60815 A OA 60815A OA 10579 A OA10579 A OA 10579A
Authority
OA
OAPI
Prior art keywords
flavin
hydrogen
dérivative
compound
alkyl
Prior art date
Application number
OA60815A
Other languages
English (en)
Inventor
Washington Osur Ayuko
Original Assignee
Radopath Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radopath Ltd filed Critical Radopath Ltd
Publication of OA10579A publication Critical patent/OA10579A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
OA60815A 1993-10-19 1996-04-18 Flavin derivatives as anti-viral agents OA10579A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939321558A GB9321558D0 (en) 1993-10-19 1993-10-19 Anti-viral agents

Publications (1)

Publication Number Publication Date
OA10579A true OA10579A (en) 2002-06-19

Family

ID=10743784

Family Applications (1)

Application Number Title Priority Date Filing Date
OA60815A OA10579A (en) 1993-10-19 1996-04-18 Flavin derivatives as anti-viral agents

Country Status (26)

Country Link
EP (1) EP0739208A1 (ro)
JP (1) JPH09505804A (ro)
CN (1) CN1140992A (ro)
AP (1) AP620A (ro)
AU (1) AU7943794A (ro)
BG (1) BG100599A (ro)
BR (1) BR9407862A (ro)
CA (2) CA2123825A1 (ro)
CO (1) CO4520283A1 (ro)
CZ (1) CZ113796A3 (ro)
EE (1) EE9600057A (ro)
GB (2) GB9321558D0 (ro)
HR (1) HRP940688A2 (ro)
HU (1) HUT76322A (ro)
IL (1) IL111338A0 (ro)
JO (1) JO1866B1 (ro)
MA (1) MA23356A1 (ro)
MD (1) MD960168A (ro)
NO (1) NO961547L (ro)
OA (1) OA10579A (ro)
PE (1) PE5596A1 (ro)
PL (1) PL314008A1 (ro)
SK (1) SK50696A3 (ro)
UY (1) UY23844A1 (ro)
WO (1) WO1995011028A1 (ro)
ZA (1) ZA948191B (ro)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07188052A (ja) * 1993-12-27 1995-07-25 Sanwa Kagaku Kenkyusho Co Ltd インターフェロン用作用効果増強剤及び該増強剤とインターフェロンとを含有する抗ウイルス活性増強組成物
US5756479A (en) * 1994-12-29 1998-05-26 Research Development Foundation Flavin adenine dinucleotide analogue inhibitors of monoamine oxidase
US9044523B2 (en) 2000-06-15 2015-06-02 Terumo Bct, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
US6933285B2 (en) * 2002-05-10 2005-08-23 The Ohio State University Flavin N-oxides: new anti-cancer agents and pathogen eradication agents
ITTO20020622A1 (it) 2002-07-16 2004-01-16 Dayco Europe Srl Gruppo integrato puleggia-smorzatore torsionale
US20060293335A1 (en) * 2002-08-02 2006-12-28 Qishou Xu Riboflavin derivative and its manufacture and uses
EP2545788A1 (de) * 2011-07-13 2013-01-16 Martin Hulliger Diätisches Mehrkomponentensystem
JP2018131410A (ja) * 2017-02-15 2018-08-23 ヒノキ新薬株式会社 カスパーゼ−３阻害剤とその用途
US11497749B2 (en) * 2017-10-24 2022-11-15 Lunella Biotech, Inc. Mitoflavoscins: targeting flavin-containing enzymes eliminates cancer stem cells (CSCS) by inhibiting mitochondrial respiration
CN114126603A (zh) * 2019-07-09 2022-03-01 帝斯曼知识产权资产管理有限公司 用核黄素或dha降低艾拉弗德的病毒活性

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4219545A (en) * 1979-03-23 1980-08-26 Collins Calvin E Treatment of infectious keratoconjunctivitis in animals
US4264601A (en) * 1979-06-12 1981-04-28 The Board Of Regents Of The University Of Oklahoma Antihypertensive agents and their use in treatment of hypertension
US4500524A (en) * 1982-09-15 1985-02-19 Trustees Of Boston University Tranquilizing and reducing or preventing seizures
WO1991002529A2 (en) * 1989-08-14 1991-03-07 John Bennett Kizer Product and method for killing abnormal vertebrate cells
JP2727471B2 (ja) * 1989-09-14 1998-03-11 三井農林株式会社 インフルエンザウィルス感染予防剤
US5192264A (en) * 1989-10-06 1993-03-09 The Beth Israel Hospital Association Methods and apparatus for treating disease states using oxidized lipoproteins
US5217716A (en) * 1990-07-18 1993-06-08 The Beth Israel Hospital Association Method for treating viral infections using oxidized lipoproteins
FR2674753B1 (fr) * 1991-04-02 1995-03-10 Jean Berque Nouvelles indications therapeutiques, en particulier pour le traitement du sida, d'un medicament deja existant et fabrique a partir d'une molecule denuee de contre-indications et d'effets indesirables.
NZ244270A (en) * 1991-09-13 1995-07-26 Eisai Co Ltd Injectable composition comprising riboflavin
WO1993010784A1 (en) * 1991-11-25 1993-06-10 University Of Michigan Therapeutic composition and method for preventing reperfusion injury
JP3073309B2 (ja) * 1992-03-27 2000-08-07 雪印乳業株式会社 シアル酸結合５−デアザフラビン系化合物

Also Published As

Publication number Publication date
CN1140992A (zh) 1997-01-22
MD960168A (ro) 1998-04-30
HUT76322A (en) 1997-08-28
HU9601006D0 (en) 1996-06-28
NO961547D0 (no) 1996-04-18
EE9600057A (et) 1996-10-15
PE5596A1 (es) 1996-04-18
GB9421099D0 (en) 1994-12-07
IL111338A0 (en) 1994-12-29
EP0739208A1 (en) 1996-10-30
AP620A (en) 1997-10-14
SK50696A3 (en) 1997-01-08
CA2174552A1 (en) 1995-04-27
CO4520283A1 (es) 1997-10-15
BR9407862A (pt) 1997-05-20
GB9321558D0 (en) 1993-12-08
ZA948191B (en) 1995-06-08
CZ113796A3 (en) 1996-11-13
BG100599A (en) 1997-02-28
JO1866B1 (en) 1995-12-27
HRP940688A2 (en) 1997-04-30
NO961547L (no) 1996-06-19
UY23844A1 (es) 1995-03-28
PL314008A1 (en) 1996-08-05
AU7943794A (en) 1995-05-08
JPH09505804A (ja) 1997-06-10
GB2283913A (en) 1995-05-24
AP9400695A0 (en) 1995-01-31
CA2123825A1 (en) 1995-04-20
WO1995011028A1 (en) 1995-04-27
MA23356A1 (fr) 1995-07-01

Similar Documents

Publication Publication Date Title
CA2032261C (en) Antiviral polyheterocyclic dimers
EP1095042B9 (en) Antiparasitic artemisinin derivatives (endoperoxides)
US20070054876A1 (en) Pharmaceutical composition promoting defecation
US20040259865A1 (en) Pyrimidone compounds and pharmaceutical compositions containing the same
OA10579A (en) Flavin derivatives as anti-viral agents
EP0262345A2 (en) Pyrroloquinoline quinones as enzyme inhibitors
WO2022152918A1 (en) Azaquinazoline derivatives for use in treating or preventing dirofilaria infection in a mammal
KR20080071182A (ko) 9-옥소아크리딘-10-아세트산 및 1-알킬아미노-1-데옥시폴리올의 염, 이들을 포함하는 약학적 조성물 및 치료 방법
US20210369699A1 (en) Treatment of lupus erythematosus using s-hydroxychloroquine
US5405850A (en) Antiviral compositions consisting of acyclovir and a 2-acetyl pyridine derivative
KR100356443B1 (ko) 페스티바이러스감염증및이와관련된질병의예방및치료방법
US5962480A (en) Drug for ameliorating brain diseases
NZ217431A (en) Synergistically antimalarial combination preparations comprising an iron(iii) chelating agent and a schizontocide
KR0133555B1 (ko) 5-플루오로우라실계 화합물에 기인한 염증의 발생을 억제할 수 있는 비-주사제 형태의 항암조성물
NO313225B1 (no) Kombinasjon av atovaquon og proguanil for behandling av protozoinfeksjoner
PT99434A (pt) Processo para a preparacao de composicoes farmaceuticas contendo derivados de xantina
JP2005112755A (ja) フェノール系誘導体を有効成分とするクリプトスポリジウム症の予防・治療剤
NZ755175A (en) Monoterpene phenol derivatives
EP0476391B1 (en) Anti-AIDS virus composition containing cepharanthine as active compound
McTier et al. UK-124, 114*, a novel avermectin for the prevention of heartworms in dogs and cats.
GB2319474A (en) Anti-viral agents
KR100408928B1 (ko) 알로에신을 함유하는 허혈성 질환의 예방 및 치료용조성물, 및 이를 포함하는 제제
Fitzgerald Colchicine and allopurinol
CN117715908A (zh) 具有整合酶抑制活性的吡啶酮化合物及其药用用途
KR100532542B1 (ko) 아르세닉산, 메타아르세나이트 또는 이들의 약제학적허용가능한 염을 함유한 에이즈 예방 및 치료용 약제 조성물